All In Biotech

Drug Trial Radar · NCT01235962

A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)

A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Pazopanib as Adjuvant Therapy for Subjects With Localized or Locally Advanced RCC Following Nephrectomy

Last checked: Nov 20, 2026Latest source record: Nov 23, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,538 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,538

Actual

Start

Nov 30, 2010

Primary completion

Oct 15, 2015

Study completion Apr 15, 2019

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Nov 8, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized Phase III study is to evaluate whether pazopanib compared with placebo can prevent or delay recurrence of kidney cancer in patients with moderately high or high risk of developing recurrence after undergoing kidney cancer surgery.

Conditions

  • Renal Cell Carcinoma (RCC)
  • Cancer

Interventions

  • pazopanibDrug

    Pazopanib monohydrochloride salt was supplied as aqueous, film-coated tablets containing 200 mg of the free base. The 200 mg tablets were oval-shaped and white in color.

  • placeboDrug

    Placebo matching pazopanib was supplied as aqueous, film-coated tablets containing 200 mg of the free base. The 200 mg tablets were oval-shaped and white in color.

  • pazopanibDrug

    Pazopanib 600 mg daily initial dose for 8-12 weeks, dose can be escalated to 800 mg daily based on safety evaluation.

  • placeboDrug

    placebo matching pazopanib daily initial dose for 8-12 weeks, dose can be escalated to 800 mg daily based on safety evaluation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease-free Survival (DFS) With Pazopanib 600 mg Daily Initial Dose vs. PlaceboTime frame: approximately 5 years

Locations

312 sites in 26 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Jonesboro, Arkansas

  • Novartis Investigative Site

    Antioch, California

  • Novartis Investigative Site

    Beverly Hills, California

  • Novartis Investigative Site

    Fresno, California

  • Novartis Investigative Site

    La Jolla, California

  • Novartis Investigative Site

    Los Angeles, California

  • Novartis Investigative Site

    Los Angeles, California

  • Novartis Investigative Site

    Los Angeles, California

  • Novartis Investigative Site

    Oakland, California

  • Novartis Investigative Site

    Sacramento, California

  • Novartis Investigative Site

    San Francisco, California

  • Novartis Investigative Site

    South San Francisco, California

  • Novartis Investigative Site

    Stanford, California

  • Novartis Investigative Site

    Vallejo, California

  • Novartis Investigative Site

    Fort Collins, Colorado

  • Novartis Investigative Site

    Washington D.C., District of Columbia

  • Novartis Investigative Site

    Fort Myers, Florida

  • Novartis Investigative Site

    Tampa, Florida

  • Novartis Investigative Site

    Athens, Georgia

  • Novartis Investigative Site

    Macon, Georgia

  • Novartis Investigative Site

    Chicago, Illinois

  • Novartis Investigative Site

    Indianapolis, Indiana

  • Novartis Investigative Site

    Iowa City, Iowa

  • Novartis Investigative Site

    Baltimore, Maryland

  • Novartis Investigative Site

    Boston, Massachusetts

  • Novartis Investigative Site

    Boston, Massachusetts

  • Novartis Investigative Site

    Boston, Massachusetts

  • Novartis Investigative Site

    Burlington, Massachusetts

  • Novartis Investigative Site

    Detroit, Michigan

  • Novartis Investigative Site

    Rochester, Minnesota

  • Novartis Investigative Site

    Saint Louis Park, Minnesota

  • Novartis Investigative Site

    St Louis, Missouri

  • Novartis Investigative Site

    Lincoln, Nebraska

  • Novartis Investigative Site

    Omaha, Nebraska

  • Novartis Investigative Site

    Omaha, Nebraska

  • Novartis Investigative Site

    Las Vegas, Nevada

  • Novartis Investigative Site

    Hackensack, New Jersey

  • Novartis Investigative Site

    Albany, New York

  • Novartis Investigative Site

    Buffalo, New York

  • Novartis Investigative Site

    New York, New York

Showing 40 of 312 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.